Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 225-231

  Glebe, Dieter ^a   Geipel, Andreas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antiviral resistance; Hepatitis B virus; Phenotypic assays; Viral fitness

Indexed keywords

ANTIVIRUS AGENT; GENOMIC DNA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DNA REPLICATION; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; ANIMAL MODEL; CLASSIFICATION; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; VIRUS REPLICATION; ASSAY; GENE AMPLIFICATION; MOLECULAR CLONING; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84904638334     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360950     Document Type: Review

References (58)

1. Dreesman JM, Baillot A, Hamschmidt L, Monazahian M, Wend UC, Gerlich WH: Outbreak of hepatitis B in a nursing home associated with capillary blood sampling. Epidemiol Infect 2006; 134: 1102-1113.
2. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
3. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049.
4. Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG: The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog 2013; 9:e1003125.
5. Vörös J, Urbanek A, Rautureau GJ, O'Connor M, Fisher HC, Ashcroft AE, Ferguson N: Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J Virol 2014; 88: 2584-2599.
6. Zoulim F, Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.e1-2.
7. Glebe D, Bremer CM: The molecular virology of hepatitis B virus. Semin Liver Dis 2013; 33: 103-112.
8. Glebe D, Urban S: Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007; 13: 22-38.
9. Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.
10. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC: Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305-313.
11. Torresi J: The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25: 97-106.
12. Sheldon J, Soriano V: Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-768.
13. Kwei K, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, Tong S: Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. J Virol 2013; 87: 2352-2357.
14. Thibault V, Aubron-Olivier C, Agut H, Katlama C: Primary infection with a lamivudineresistant hepatitis B virus. AIDS 2002; 16: 131- 133.
15. Günther S, Li BC, Miska S, Krüger DH, Meisel H, Will H: A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 5437-5444.
16. Durantel D, Brunelle M-N, Gros E, Carrouee- Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F: Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005; 34(suppl 1):S34-S43.
17. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
18. Glebe D, Berting A, Broehl S, Naumann H, Schuster R, Fiedler N, Tolle TK, Nitsche S, Seifer M, Gerlich WH, Schaefer S: Optimised conditions for the production of hepatitis B virus from cell culture. Intervirology 2001; 44: 370-378.
19. Delaney WE 4th, Isom HC: Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998; 28: 1134-1146.
20. Lucifora J, Durantel D, Belloni L, Barraud L, Villet S, Vincent IE, Margeridon-Thermet S, Hantz O, Kay A, Levrero M, Zoulim F: Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J Gen Virol 2008; 89: 1819-1828.
21. Ren S, Nassal M: Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 2001; 75: 1104-1116.
22. Dion S, Bourgine M, Godon O, Levillayer F, Michel M-L: Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol 2013; 87: 5554-5563.
23. Fu L, Cheng YC: Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovirresistant virus. Antimicrob Agents Chemother 2000; 44: 3402-3407.
24. Qi X, Xiong S, Yang H, Miller M, Delaney WE: In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362.
25. Sun D, Nassal M: Stable HepG2- and Huh7- based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006; 45: 636-645.
26. Jursch CA, Gerlich WH, Glebe D, Schaefer S, Marie O, Thraenhart O: Molecular approaches to validate disinfectants against human hepatitis B virus. Med Microbiol Immunol 2002; 190: 189-197.
27. Sampah ME, Shen L, Jilek BL, Siliciano RF: Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci USA 2011; 108: 7613-7618.
28. Curran-Everett D: Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000; 279:R1-R8.
29. Bland JM, Altman DG: Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
30. Glebe D: Attachment sites and neutralising epitopes of hepatitis B virus. Minerva Gastroenterol Dietol 2006; 52: 3-21.
31. Glebe D: Recent advances in hepatitis B virus research: a German point of view. World J Gastroenterol 2007; 13: 8-13.
32. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C: Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002; 99: 15655-15660.
33. Drexler JF, Geipel A, König A, et al: Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci USA 2013; 110: 16151-16156.
34. Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Deny P, Zoulim F: In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009; 136: 168-176.e2.
35. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F: Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001; 75: 5084-5089.
36. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH: Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003; 77: 9511-9521.
37. Köck J, Glebe D: Hepatitis B virus infection of primary tupaia hepatocytes; in Von Weizsäcker F, Roggendorf M (eds): Models of Viral Hepatitis. Basel, Karger, 2005, vol 25, pp 96- 105.
38. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D: N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol 2011; 55: 29-37.
39. Glebe D, Gerlich WH: Study of the endocytosis and intracellular localization of subviral particles of hepatitis B virus in primary hepatocytes. Methods Mol Med 2004; 96: 143-151.
40. Wittkop L, Schwarz A, Cassany A, Grün- Bernhard S, Delaleau M, Rabe B, Cazenave C, Gerlich W, Glebe D, Kann M: Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cell Microbiol 2010; 12: 962-975.
41. Watanabe T, Sorensen EM, Naito A, Schott M, Kim S, Ahlquist P: Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc Natl Acad Sci USA 2007; 104: 10205-10210.
42. Pairan A, Bruss V: Functional surfaces of the hepatitis B virus capsid. J Virol 2009; 83: 11616-11623.
43. Bremer CM, Bung C, Kott N, Hardt M, Glebe D: Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol 2009; 11: 249-260.
44. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D: Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009; 49: 1621-1629.
45. Sureau C, Salisse J: A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013; 57: 985-994.
46. Schulze A, Gripon P, Urban S: Hepatitis B virus infection initiates with a large surface protein- dependent binding to heparan sulfate proteoglycans. Hepatology 2007; 46: 1759- 1768.
47. Köck J, Baumert TF, Delaney WEt, Blum HE, von Weizsäcker F: Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 2003; 38: 1410-1418.
48. Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grün S, Bulavaite A, Sasnauskas K, Gerlich WH: Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005; 129: 234-245.
49. Gripon P, Cannie I, Urban S: Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622.
50. Baumert TF, Yang C, Schurmann P, Köck J, Ziegler C, Grullich C, Nassal M, Liang TJ, Blum HE, von Weizsäcker F: Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology 2005; 41: 247-256.
51. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, Krawczynski K: Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49: 1483-1491.
52. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, Greten H, Petersen J: Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33: 981-988.
53. Dandri M, Petersen J: Chimeric mouse model of hepatitis B virus infection. J Hepatol 2012; 56: 493-495.
54. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M: Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012; 55: 685-694.
55. Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM, Rogiers X, Gocht A, Köck J, Blum HE, von Weizsä cker F, Petersen J: Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with Tupaia hepatocytes. J Hepatol 2005; 42: 54-60.
56. Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M: The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867.
57. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
58. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M: Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-662.